US equities
|
NVDA
$235.25
▲+1.90%
MU
$1,079.12
▼-1.67%
TSLA
$372.64
▲+5.23%
SPCX
$157.61
▲+6.44%
SNDK
$1,719.70
▼-3.80%
AMD
$631.05
▲+2.49%
STX
$826.95
▼-12.54%
WDC
$404.56
▼-12.54%
NVDA
$235.25
▲+1.90%
MU
$1,079.12
▼-1.67%
TSLA
$372.64
▲+5.23%
SPCX
$157.61
▲+6.44%
SNDK
$1,719.70
▼-3.80%
AMD
$631.05
▲+2.49%
STX
$826.95
▼-12.54%
WDC
$404.56
▼-12.54%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Summit Therapeutics
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
Today 2:30 EDT
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
September 28, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026
September 22, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
September 15, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China
September 13, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China
September 02, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
August 25, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
August 25, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
August 12, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
August 05, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
July 23, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
July 22, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
RCUS
SMMT
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
July 22, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
July 16, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
July 14, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Announces Proposed Public Offering of Common Stock
June 09, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
June 04, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
May 31, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
May 30, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026
April 30, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
March 27, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Summit Therapeutics to Present at Upcoming Investor Conferences
February 26, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025
February 23, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026
February 17, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 30, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
January 29, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)
January 12, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC
January 12, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 09, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From
Summit Therapeutics
Via
Business Wire
Tickers
SMMT
